Dr. Gomella on Immunotherapy Developments in Prostate Cancer

Leonard Gomella, MD
Published: Monday, Mar 19, 2018



Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

The customized immunotherapy that was approved almost 8 years ago, sipuleucel-T (Provenge), continues to be one of the mainstays of treatment for patients with advanced prostate cancer, says Gomella. Some institutional trials and other large national trials are looking at combining sipuleucel-T with other agents, such as enzalutamide (Xtandi).

An immuno-oncology drug with a novel antiandrogen treatment like enzalutamide may prove to be a benefit to patients with prostate cancer. Taking these advanced drugs and using them together in a long-term sequential fashion may prove to be beneficial, according to Gomella.
 
SELECTED
LANGUAGE


Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

The customized immunotherapy that was approved almost 8 years ago, sipuleucel-T (Provenge), continues to be one of the mainstays of treatment for patients with advanced prostate cancer, says Gomella. Some institutional trials and other large national trials are looking at combining sipuleucel-T with other agents, such as enzalutamide (Xtandi).

An immuno-oncology drug with a novel antiandrogen treatment like enzalutamide may prove to be a benefit to patients with prostate cancer. Taking these advanced drugs and using them together in a long-term sequential fashion may prove to be beneficial, according to Gomella.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x